Compare KB Financial Group, Inc. (KB) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Medpace Holdings Inc — how do they compare? KB Financial Group, Inc. trades at $121.96 (market cap $42.62B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: KB Financial Group, Inc. is far larger — about 2.5× Medpace Holdings Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Medpace Holdings Inc for 14 Days on average.
| KB | MEDP | |
|---|---|---|
Market Cap | $42.62B | $16.82B |
Volume | 164,291 | 223,093 |
Sector | Financials | Health |
52-Week High | $132.88 | $630.19 |
52-Week Low | $77.50 | $393.42 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $215.53T | $16.44B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and improving profitability metrics. Technical indicators suggest a neutral near-term outlook, while analyst sentiment leans cautious with a 66.7% hold rating. Recent news highlights institutional interest and positive momentum coverage from financial media.
The outlook for KB appears balanced with attractive valuation metrics including a P/E of 9.68 and P/B of 0.94 suggesting potential undervaluation. However, the mixed analyst consensus and elevated EV/EBITDA of 21.71 warrant caution. Key risks include exposure to South Korean economic conditions and banking sector volatility, while opportunities lie in continued earnings growth and dividend potential.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
